ProShare Advisors
ADCT icon

ProShare Advisors’s ADC Therapeutics ADCT Stock Holding History

ProShare Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.5K Sell
14,799
-928
-6% -$3.66K ﹤0.01% 1773
2025
Q4 		$55.5K Buy
15,727
+3,339
+27% +$13.5K ﹤0.01% 1945
2025
Q3 		$49.6K Sell
12,388
-2,467
-17% -$7.78K ﹤0.01% 1934
2025
Q2 		$39.8K Sell
14,855
-2,750
-16% -$5.79K ﹤0.01% 2023
2025
Q1 		$24.8K Sell
17,605
-5,296
-23% -$9K ﹤0.01% 2023
2024
Q4 		$45.6K Buy
22,901
+7,535
+49% +$19.7K ﹤0.01% 2191
2024
Q3 		$48.4K Buy
+15,366
New +$48.5K ﹤0.01% 1983

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return